



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

19 April 2010,
Updated 28 June 2010
EMA/251818/2010

Outcomes of the evaluation of the European medicines agency – the Future sustainability of the system

Agenda

30 June 2010, 8.30 to 18.00
Room 2A

Time	Chairs/Panel members/Topics	Speakers
08.30-9.00	Registration	
9.00 -9.15 15 min	Opening of the conference	Nils Behrndt (European Commission)
9.15-9.30 15 min	Preparing the Agency for tomorrow's challenges	Thomas Lönngren (EMA)
9.30-10.15 45 min	Presentation of outcomes of the evaluation	Pascale Augé, Florent Gomez-Bonnet (Ernst & Young)
10.15-11.45 1 hr 30 min	SESSION 1: ARCHITECTURE OF THE EUROPEAN MEDICINES AGENCY Session chair Patrick Le Courtois (EMA) Panel: Daniel Brasseur (PDCO), Kerstin Westermark (COMP), Bruno Flamion (SAWP), Jan Mazag (HMA), Christoph Thalheim (EMSP), Michael Doherty (EFPIA)	



Time	Chairs/Panel members/Topics	Speakers
	<p>Topic:</p> <p>Improving the architecture of the EMA to make it better equipped for the future</p> <ul style="list-style-type: none"> - structure and organisation of the CHMP - addressing the complexities of interaction between committees - assuring capacity and capability to deal with current workload - interaction with the industry throughout lifecycle of medicines <p>Discussion</p> <p>Conclusions of the session</p>	<p>Eric Abadie (CHMP)</p> <p>All</p> <p>Arielle North (EMA)</p>
<p>11.45-12.05</p> <p>20 min</p>	<p>Break</p>	
<p>12.05-13.35</p> <p>1 hr 30 min</p>	<p style="text-align: center;">SESSION 2: EUROPEAN MEDICINES NETWORK</p> <p>Session chair</p> <p>Aginus Kalis (HMA)</p> <p>Panel:</p> <p>Martina Cvelbar (HMA), Martin Schneidereit (IFAH-Europe), Beata Stepniewska (EGA), Michael Wilks (CPME)</p> <p>Topics:</p> <p>1. Assure long-term availability of resources and the highest possible level of expertise</p> <ul style="list-style-type: none"> - increasing the involvement of scientific resources across the network for the Agency - other ways to organise the application review process (cross-border cooperation, splitting dossiers) <p>Discussion</p> <p>2. Coordinating role of the Agency within the network – clarifying roles and responsibilities</p>	<p>Jean Marimbert (HMA)</p> <p>All</p> <p>Peter Arlett (EMA)</p>

Time	Chairs/Panel members/Topics	Speakers
	<p>Discussion</p> <p>Conclusions of the session</p>	<p>All</p> <p>Martin Terberger (European Commission)</p>
<p>13.35-14.35</p> <p>1 hr</p>	<p>Lunch</p>	
<p>14.35-15.20</p> <p>45 min</p>	<p style="text-align: center;">SESSION 3: TOPICS SPECIFIC TO VETERINARY MEDICINAL PRODUCTS</p> <p>Chair:</p> <p>David Mackay (EMA)</p> <p>Panel:</p> <p>Anja Holm (CVMP), Frank Verheijen (Netherlands), Kornelia Grein (EMA), Brigitte Boenisch (IFAH-Europe), Inge Sandberg (EGGVP), Jan Vaarten (FVE)</p> <p>Topics:</p> <p>Architecture of the Agency committees in support of veterinary medicines</p> <p>Supporting the product development pipeline</p> <p>Veterinary dimensions to the European Medicines Network</p> <p>Discussion</p> <p>Conclusions of the session</p>	<p>Brigitte Boenisch (IFAH-Europe)</p> <p>All</p> <p>Fia Westerholm (EMA)</p>
<p>15.20-16.45</p> <p>1 hr 25 min</p>	<p style="text-align: center;">SESSION 4: FEE SYSTEM OF THE EUROPEAN MEDICINES AGENCY</p> <p>Session chair</p> <p>Andrzej Ryś (European Commission)</p> <p>Panel:</p> <p>Andreas Pott (EMA), Pat O'Mahony (Management Board), Christa Wirthumer-Hoche (HMA), Edwin Ruighaver (EFPIA), Emmanuel Chantelot (EBE), Neil Craven (IFAH-Europe)</p>	

Time	Chairs/Panel members/Topics	Speakers
	<p>Topic:</p> <p>Ensuring long-term sustainability</p> <p>Discussion</p> <p>Conclusions of the session</p>	<p>Ulrike Nagl (EMA)</p> <p>All</p> <p>Zaide Frias (EMA)</p>
<p>16.45-17.00</p> <p>15 min</p>	<p>Break</p>	
<p>17.00-17.55</p> <p>55 min</p>	<p style="text-align: center;">SESSION 5: ROAD MAP</p> <p>Session chair</p> <p>Thomas Lönngren (EMA)</p> <p>Panel</p> <p>Dagmar Roth-Behrendt (European Parliament), Kent Woods (HMA), Hubertus Cranz (AESGP), Wills Hughes-Wilson (EuropaBio), Brigitte Boenisch (IFAH- Europe)</p> <p>Topic:</p> <p>High-level Overview of the Outcome of the Public Consultation</p> <p>Discussion</p>	<p>Noël Wathion (EMA)</p> <p>All</p>
<p>17.55-18.00</p> <p>5 min</p>	<p>Closure</p>	<p>Thomas Lönngren</p>